

# The Examination of Antimicrobial Soft Silicone Foam Dressing with Regards to Partial Thickness Burns

Author: Dr. Herbert Meites MD, Dr. Mason Jett MD, Dr. Stephen Gauthier MD, Kenna Wilson RN MSN, Paul Silverstein Burn Center Oklahoma City, OK

## BACKGROUND:

Examination of the burn wound has been an integral aspect of treatment, since this allows for wound progression to be monitored. This is hindered by treatments that either leaves a residue, or becomes adherent which prevents inspection of the wound.

**Mepilex® Ag**, manufactured by Mölnlycke Health Care, utilizes soft silicone (**Safetac®** Technology) to provide a dressing that may reduce amount of adherence to the burn wound. The **Safetac** Technology is designed to allow the dressing to float over open moist tissue, while remaining attached to intact tissue.

## PURPOSE:

To examine the use of **Mepilex Ag** for the treatment of Partial Thickness Burns.

## METHOD:

The **Mepilex Ag** will be placed on partial thickness injuries less than 72 hours post burn. The patient will also be asked daily to demonstrate and perform range of motion exercises. The **Mepilex Ag**, will be removed at day 6 to 7 for wound evaluation and to determine if tearing of the new epithelium occurs. Digital images will be obtained for visual documentation.

## CASE PRESENTATION:

### Case Study # 1



Initial



Day 5



Day 9  
Prior to removal



Day 9



Day 15

### Case Study # 2



Initial



Application



Day 3  
Range of Motion



Day 6  
Range of Motion



Day 3  
Dressing removal

## REFERENCE:

1. Silver Deposition and Tissue Staining Associated with Wound Dressings Containing Silver Michael Walker, PhD, CA; Christine A. Cochrane, PhD; Philip G. Bowler, MPhil; David Parsons, PhD; and Peter Bradshaw. *Ostomy/Wound Management* - ISSN: 0889-5899 - Volume 52 - Issue 1 - January 2006 - Pages: 42 - 50
2. Herndon, D.N. (Ed.). *Total burn care* (2nd ed.). London: W.B.Saunders.
3. Monafó WW. Initial management of burns. *N Engl J Med* 1996; 335(21): 1581-6.

## RESULTS:

A total of 18 patients were evaluated with a mean TBSA of 7.28 with a range from 1% to 18%. Of the 18 patients, 11 had involvement of at least one joint and all patients demonstrated the ability to perform range of motion exercises throughout the course of treatment. One patient had burns that required grafting.

## CONCLUSION:

The **Mepilex Ag** provided antimicrobial protection that left the burn injury with a clean appearance. The **Safetac** Technology prevented the **Mepilex Ag** from adhering to the wound, thereby, giving the clinician the opportunity to either examine the wound or leave it intact for up to seven days at their discretion. Since the injuries were able to be examined, the physician felt that the **Mepilex Ag** did not delay the decision to graft burns requiring surgical intervention.

## PRODUCT NOTATION

Mepilex® Ag and Safetac®,  
Mölnlycke Health Care US, LLC. Norcross, GA.

## FINANCIAL ASSISTANCE/DISCLOSURE

Mölnlycke Health Care US, LLC. provided assistance with poster design.

